drugset / Trial / NCT04165031
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
RandomizedParallel-groupOpen-labelTreatment
Summary
The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.
Timeline
- Start
- 2019-11-28
- Primary completion
- 2020-10-30
- Completion
- 2020-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3499446 | Small molecule | — | Oral |
| Background | Abemaciclib | Small molecule | — | Oral |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Background | Erlotinib | Small molecule | — | Oral |